Clinical trials
Locally Advanced Gastric Adenocarcinoma clinical trials
Below are recruiting locally advanced gastric adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 196 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Mobile, AlabamaAges 18 years+ - NCT07584135RecruitingPhase 3
JS107, Toripalimab, and Chemotherapy for Advanced Stomach Cancer
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18 years+ - NCT06846996Recruiting
Study of trastuzumab deruxtecan for advanced stomach cancer
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
BeijingAges 18 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Aurora, ColoradoAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06510010RecruitingPhase 2
Chemo plus H. pylori treatment for advanced stomach cancer
This trial tests whether adding H. pylori bacteria treatment to standard chemotherapy (before and after surgery) can improve outcomes for people with locally advanced stomach cancer. It combines oxaliplatin and S-1 chemo with antibiotics to clear the infection.
GuangzhouAges 18–75 - NCT07325630RecruitingPhase 2
Perioperative study of IBI363 for MHC-II-negative advanced stomach cancer
This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT05226169RecruitingPhase 3
Iron medicine plus standard therapy for advanced stomach cancer
This Phase 3 study tests whether giving ferric carboxymaltose (an IV iron treatment) helps people with advanced stomach or stomach–esophagus cancer and iron-deficiency anemia. The goal is to improve safety and how well the standard first-line cancer treatment works.
SeoulAges 19 years+ - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07546812RecruitingPhase 2
Testing Denikitug for advanced stomach and esophageal cancer
This study tests a new drug called denikitug, alone or combined with other cancer treatments, for patients with advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after initial treatment. The drug targets immune cells to help your body fight cancer.
Boston, MassachusettsAges 18 years+ - NCT06630130RecruitingPhase 2
Surgery and drug therapy for advanced stomach cancer
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
SeoulAges 19 years+ - NCT07427992Recruiting
Study of zolbetuximab for stomach cancer with claudin 18.2
This trial is looking at a drug called zolbetuximab, given with chemotherapy, for people with a certain type of stomach or gastroesophageal junction cancer that has spread and has high levels of a protein called claudin 18.2. The goal is to see how well it works in real-world settings.
MilanAges 18–100 - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
DoradoAges 18 years+ - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT05960955RecruitingPhase 2
Testing immunotherapy plus chemo around the time of gastric surgery
This study tests whether adding cadonilimab (and possibly AK117) to chemotherapy can improve outcomes for people with resectable stomach or stomach–esophagus cancer. It aims to see if this combination works better than chemotherapy alone, while still being safe around surgery.
TianjinAges 18–75 - NCT05671822RecruitingPhase 2
Study of targeted drugs for HER2-positive advanced stomach cancer
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70
Hear when a new Locally Advanced Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced gastric adenocarcinoma?
- Yes. Clin2 currently lists 196 recruiting locally advanced gastric adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced gastric adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced gastric adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.